Trials / Terminated
TerminatedNCT02021929
Sorafenib for Hepatopulmonary Syndrome
Sorafenib in Patients With Hepatopulmonary Syndrome: A Double-Blind Randomized Clinical Trial
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- University of Pennsylvania · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this clinical trial is to determine the safety and effects of the study drug, sorafenib, in adults diagnosed with hepatopulmonary syndrome (HPS). The study will evaluate how well the drug is tolerated and its effect on the level of oxygen in the blood and the function of the lung vessels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib | Sorafenib is a kinase inhibitor indicated for the treatment of: * Unresectable hepatocellular carcinoma * Advanced renal cell carcinoma * Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment |
| DRUG | Placebo |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2018-01-01
- Completion
- 2018-01-01
- First posted
- 2013-12-27
- Last updated
- 2019-04-25
- Results posted
- 2019-04-25
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02021929. Inclusion in this directory is not an endorsement.